MARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]
Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., Aug. 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-08-10 04:48:492022-08-10 04:49:41CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)
Melbourne, Australia – 8 August 2022 Link here : Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has accepted for review Acrux’s application for a generic version (Abbreviated New Drug Application or ‘ANDA’) of cold sore treatment, Acyclovir Cream, 5%. Key Highlights Acrux has […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-08-08 07:26:082022-08-08 11:31:01Acrux’s sixth generic application accepted by FDA for review
Melbourne, Australia – 2 August 2022 link here: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of its 510(k) clearance to market application, which connects GlaxoSmithKline® (GSK) Ventolin®, Advair®, and Flovent® pressurized metered-dose inhaler (pMDI) users […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-08-03 03:47:252022-08-03 03:47:25Adherium submits FDA 510(k) application for next generation Hailie sensor for GSK pMDI inhalers
Link to full article Key Highlights: • US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company • Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of negotiations with […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-30 01:13:022022-05-30 01:13:02US FDA Clears IND for Cynata’s Phase 2 Clinical Trial of CYP-001 in GvHD
Link to full article Patients with Parkinson’s disease are being given life-changing smart watches that allow doctors to remotely assess their condition in a pioneering project to revolutionise NHS care. The cutting-edge gadget containing sensors, known as a Parkinson’s Kinetigraph (PKG), is worn around the clock for six days to monitor patients’ movements at home. […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-24 05:45:102022-05-24 05:45:10Parkinson’s patients benefit from revolutionary watch on the NHS to manage care at home
Link to full article Melbourne, Australia; 21 April 2022: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to announce enrolment of initial patients in a clinical trial of CYP-006TK as a potential treatment for diabetic foot ulcers (DFU). Subjects are now being followed as planned for […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-24 05:20:242022-05-24 05:20:24Arlington woman first in Texas to get smart knee replacement
Link to full article April 14, 2022 – Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of results from the Company’s CARDEA clinical trial, a Phase […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-24 04:29:472022-05-24 04:29:47CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care
Link to full article MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-05-24 04:23:092022-05-24 04:23:09Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update
/in Armata PharmaceuticalsMARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]
CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)
/in CalcimedicaStudy provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., Aug. 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced […]
Acrux’s sixth generic application accepted by FDA for review
/in AcruxMelbourne, Australia – 8 August 2022 Link here : Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has accepted for review Acrux’s application for a generic version (Abbreviated New Drug Application or ‘ANDA’) of cold sore treatment, Acyclovir Cream, 5%. Key Highlights Acrux has […]
Adherium submits FDA 510(k) application for next generation Hailie sensor for GSK pMDI inhalers
/in AdheriumMelbourne, Australia – 2 August 2022 link here: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced submission to the US Food and Drug Administration (FDA) of its 510(k) clearance to market application, which connects GlaxoSmithKline® (GSK) Ventolin®, Advair®, and Flovent® pressurized metered-dose inhaler (pMDI) users […]
US FDA Clears IND for Cynata’s Phase 2 Clinical Trial of CYP-001 in GvHD
/in BioSciences Managers, Cynata, UncategorisedLink to full article Key Highlights: • US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company • Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of negotiations with […]
Parkinson’s patients benefit from revolutionary watch on the NHS to manage care at home
/in BioSciences Managers, GKCLink to full article Patients with Parkinson’s disease are being given life-changing smart watches that allow doctors to remotely assess their condition in a pioneering project to revolutionise NHS care. The cutting-edge gadget containing sensors, known as a Parkinson’s Kinetigraph (PKG), is worn around the clock for six days to monitor patients’ movements at home. […]
Cynata Advances Clinical Trial in Diabetic Foot Ulcers
/in BioSciences Managers, CynataLink to full article Melbourne, Australia; 21 April 2022: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to announce enrolment of initial patients in a clinical trial of CYP-006TK as a potential treatment for diabetic foot ulcers (DFU). Subjects are now being followed as planned for […]
Arlington woman first in Texas to get smart knee replacement
/in BioSciences Managers, Canary MedicalLink to full article
CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care
/in Calcimedica, UncategorisedLink to full article April 14, 2022 – Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of results from the Company’s CARDEA clinical trial, a Phase […]
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
/in Armata Pharmaceuticals, UncategorisedLink to full article MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is […]